LYCADEX® BioPharma - Dextrose monohydrate, low endotoxin, USP, EP, JP

PEARLITOL® CR-H co-processed mannitol HPMC is a direct compression excipient providing functional properties of binder as well as controlled release to your tablet. PEARLITOL® CR-H can be used in both pharmaceutical and nutraceutical oral dosage forms.

PEARLITOL® 200 INH mannitol has all the key attributes for its use as an effective carrier in drypowder inhalers (DPI).Key benefits:
• Narrow particle size distribution
• Suitable particle size as inhalation carrier
• Enhances drug formulation stability
• Reduced chemical interactions with APIs...

Delivering secure supply with the right partner. Trust is the most essential ingredient.

Maltodextrins and dried glucose syrups are starch hydrolysis products with a dextrose equivalent. GLUCIDEX® is a carbohydrate source in infant and enteral foods.

A range of superdisintegrants for different formulation needs.

Suitable for use in biopharmaceutical manufacturing and as an excipient for injectable dosage forms.

This excipient is used as filler for gelatin capsules and binder for direct compression. LYCATAB® C and C-LM combines the disintegration power of starch grains with the high cohesion and good compressibility.

Partially hydrolyzed starch for solid dosage forms, used as a binder for wet granulation and as diluent for direct compression.

Natural pregelatinized starch LYCATAB® PGS: solid dosage forms. This excipient is used as a binder for wet granulation.

Roquette’s LYCOAT® range is a major breakthrough in aqueous film coating and film forming.

Native starches of plant origins : Maize, wheat and potato. Extra white maize starch has a disintegration function and can be used as insoluble diluents.

Delivering secure supply with the right partner. Trust is the most essential ingredient.

The new facility will focus on the research of excipients for oral dosage forms, drug delivery systems, nutraceutical APIs and innovative pharma ingredients

Discover the wide range of products by Roquette in Pharmaceuticals and Neutraceuticals

The ramping up of vaccine manufacturing demand amid the COVID-19 pandemic had an initial impact on cell and gene therapy production but the regenerative medicine sector has largely weathered the storm, according to senior industry figures in a recent panel discussion at the CPHI Festival of Pharma virtual event.